GlassScriptPhysician profile
Ali S Anwar
NPI 1710328703
$3,882.12
in general payments reported to CMS, 2019-2025
26 companies · $1,580 in 2025
The $1,580 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2022: $615 · 2023: $932 · 2024: $542 · 2025: $1,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,053.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $440.37 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $333.85 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $328.68 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $280.56 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $279.11 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Corium, LLC | $253.67 | 2022-2024 | Azstarys, Adlarity |
| Teva Pharmaceuticals USA, INC. | $240.61 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $220.73 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $203.66 | 2024-2025 | Cobenfy |
| Harmony Biosciences LLC | $199.00 | 2022-2025 | Wakix |
| Axsome Therapeutics, INC. | $180.79 | 2022-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $149.02 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Indivior INC. | $109.16 | 2019-2023 | Perseris |
| Alkermes, INC. | $87.23 | 2022-2023 | Lybalvi, Aristada, Vivitrol |
| Supernus Pharmaceuticals, INC. | $85.73 | 2023-2025 | Qelbree, Qelbree |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $81.36 | 2024-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $68.90 | 2023 | Trintellix |
| Noven Therapeutics, LLC | $56.22 | 2024-2025 | Secuado, Xelstrym |
| Idorsia Pharmaceuticals US INC | $54.80 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $46.31 | 2025 | Loreev Xr |
| Bausch Health US, LLC | $41.14 | 2023 | Aplenzin, Wellbutrin |
| Braeburn INC. | $40.33 | 2023 | Brixadi |
| Merck Sharp & Dohme LLC | $30.25 | 2022-2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $29.17 | 2022 | |
| Collegium Pharmaceutical, INC. | $24.34 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $17.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.